Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran

Seyed Mehdi Mirsaeidi, Payam Tabarsi, Kaveh Khoshnood, Majid Valiollah Pooramiri, Ali Rowhani-Rahbar, Seyed Davood Mansoori, Heydar Masjedi, Soheyla Zahirifard, Foroozan Mohammadi, Parisa Farnia, Mohammad Reza Masjedi, Ali Akbar Velayati

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Setting: Masih Daneshvari Hospital, Tehran, Iran, 2000-2002. Objective: To evaluate the effectiveness of multiple drug-resistant tuberculosis (MDR-TB) treatment for the first time in Iran. Design: All cases of MDR-TB with complete follow-up data were recruited and results of their treatments were evaluated. Results: MDR-TB treatment was initiated with 5.23 drugs, on average. Isoniazid, amikacin, and ofloxacin were present in the drug regimen of all patients. Average duration of the treatment was 18.5 months (range, 7-36). Over 76% of the patients responded to the treatment (negative smear and culture). Cure and probable cure were documented in seven (41.2%) and four (23.5%) of the patients, respectively. No failure in the treatment occurred when cycloserine was present in the treatment regimen. Conclusion: A majority of the MDR-TB patients in Iran can be cured with the use of appropriate treatment regimens. An even greater success could be achieved by providing more second-line drugs.

Original languageEnglish (US)
Pages (from-to)317-322
Number of pages6
JournalInternational Journal of Infectious Diseases
Issue number6
StatePublished - Nov 2005
Externally publishedYes


  • Iran
  • Multiple drug-resistant tuberculosis
  • Treatment

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases


Dive into the research topics of 'Treatment of multiple drug-resistant tuberculosis (MDR-TB) in Iran'. Together they form a unique fingerprint.

Cite this